This review concluded that statins significantly decreased the risk of atrial fibrillation, with the benefit seemingly more pronounced in secondary rather than primary prevention. Lack of reporting of the review process, the potential for missed trials, substantial variation between the included trials and their methodological limitations, mean the reliability and applicability of the results and overall conclusions are uncertain.
Authors' objectives
To investigate whether statins could reduce the risk of atrial fibrillation.
Searching
PubChem Compound, MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL) and Web of Science were searched for studies published in English up to December 2010; examples of the search keywords used were given.
Study selection
Randomised controlled trials (RCTs) that compared a statin with control treatment or placebo, regardless of the background therapy in either group, were eligible for inclusion. Trials had to report the incidence or recurrence of atrial fibrillation.
In included trials, the most frequently studied statin was atorvastatin; pravastatin was used in the most patients due to the size of the trials evaluating this statin. The statin was compared with placebo or usual care (where detailed). Most included RCTs diagnosed atrial fibrillation using serial electrocardiograph ECGs and/or 24-hour Holter ECG monitoring.
The authors did not state how many reviewers selected studies for the review.
Assessment of study quality
The quality of the RCTs was assessed using the Jadad scale.
The authors did not state how many reviewers assessed study quality.
Data extraction
Data on the incidence of atrial fibrillation were extracted on an intention-to-treat basis, and odds ratios with 95% confidence intervals calculated.
The authors did not state how many reviewers extracted data.
Methods of synthesis
Summary odds ratios and 95% confidence were calculated using a fixed-effect (Mantel-Haenszel) model if no statistically significant heterogeneity was observed; a random-effects model was used where significant heterogeneity was detected. Heterogeneity was assessed using Χ² and Ι².
Sensitivity analyses were conducted to investigate the impact of trial quality, the statin used and the population; further post hoc analyses were conducted.
